The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials
Open accessAbstract
OBJECTIVE: To summarise the effect of primary prevention with lipid lowering drugs on coronary heart disease events, coronary heart disease mortality, and all cause mortality. DESIGN: Meta-analysis. IDENTIFICATION: Systematic search of the Medline database from January 1994 to June 1999 for English language studies examining drug treatment for lipid disorders (use of the MeSH terms "hyperlipidemia" and "anticholesteremic agents," keyword searches for individual drug names, and a search strategy for identifying randomised trials to capture relevant articles); identification of older studies through systematic reviews and hand search of bibliographies. INCLUSION CRITERIA: All randomised trials of at least one year's duration that examined drug treatment for patients with no known coronary heart disease, cerebrovascular disease, or peripheral vascular disease and that measured clinical end points, including all cause mortality, coronary heart disease mortality, and non-fatal myocardial infarctions. DATA EXTRACTION: Review of the articles and extracted relevant data by two authors separately, with disagreements resolved by consensus. RESULTS: Four studies met eligibility criteria. Drug treatment reduced the odds of a coronary heart disease event by 30% (summary odds ratio 0.70, 95% confidence interval 0.62 to 0.79) but not the odds of all cause mortality (0.94, 0.81 to 1.09). When statin drugs were considered alone, no substantial differences in results were found. CONCLUSIONS: Treatment with lipid lowering drugs lasting five to seven years reduces coronary heart disease events but not all cause mortality in people with no known cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Prescribing Personalized Nutrition for Cardiovascular Health: Are We Ready?
Juma, S., Imrhan, V., Vijayagopal, P., & Prasad, C. (2014) · Lifestyle Genomics · doi:10.1159/000370213 · Cited by 1,891
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 867
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
(1984) · JAMA · doi:10.1001/jama.251.3.365 · Cited by 643
Salonen, R., Nyyssönen, K., Porkkala, E., Rummukainen, J., Belder, R., Park, J.-S., & Salonen, J. T. (1995) · Circulation · doi:10.1161/01.cir.92.7.1758 · Cited by 540
Cited by
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Critchley, J. A., & Capewell, S. (2003) · JAMA · doi:10.1001/jama.290.1.86 · Cited by 1,089
Comparative quantification of health risks conceptual framework and methodological issues
Murray, C. J., Ezzati, M., Lopez, A. D., Rodgers, A., & Vander Hoorn, S. (2003) · Population Health Metrics · doi:10.1186/1478-7954-1-1 · Cited by 887
Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy
Chapman, R. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1147 · Cited by 506
Pantoja, T., & Letelier, L. M. (2003) · Revista médica de Chile · doi:10.4067/s0034-98872003001000017 · Cited by 386
(2003) · OECD Health Working Papers · doi:10.1787/230112362071 · Cited by 381
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Mann, K., Lehert, P., & Morgan, M. Y. (2004) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000108656.81563.05 · Cited by 364
Akosah, K. O., Schaper, A., Cogbill, C., & Schoenfeld, P. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00187-6 · Cited by 351
Thavendiranathan, P. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.21.2307 · Cited by 351
Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA study
Marrugat, J., Subirana, I., Comín, E., Cabezas, C., Vila, J., Elosua, R., Nam, B.-H., Ramos, R., Sala, J., Solanas, P., et al. (2007) · Journal of Epidemiology and Community Health · doi:10.1136/jech.2005.038505 · Cited by 322
Advances in the prevention of Alzheimer's disease and dementia
Solomon, A., Mangialasche, F., Richard, E., Andrieu, S., Bennett, D. A., Breteler, M., Fratiglioni, L., Hooshmand, B., Khachaturian, A. S., Schneider, L. S., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12178 · Cited by 319
Young, R. P., Hopkins, R., & Eaton, T. E. (2007) · European Respiratory Journal · doi:10.1183/09031936.00021707 · Cited by 306
Statins for the primary prevention of cardiovascular disease
Taylor, F., Ward, K., Moore, T. H., Burke, M., Davey Smith, G., Casas, J. P., & Ebrahim, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub4 · Cited by 305
Statin Therapy and Risks for Death and Hospitalization in Chronic Heart Failure
Go, A. S., Lee, W. Y., Yang, J., Lo, J. C., & Gurwitz, J. H. (2006) · JAMA · doi:10.1001/jama.296.17.2105 · Cited by 291
Blum, A., & Shamburek, R. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.022 · Cited by 287
Lower-Extremity Peripheral Arterial Disease among Patients with End-Stage Renal Disease
O’Hare, A., & Johansen, K. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12122838 · Cited by 283
Drug Treatment of Hyperlipidemia in Women
Walsh, J. M. E. (2004) · JAMA · doi:10.1001/jama.291.18.2243 · Cited by 270
Matthews, A., Herrett, E., Gasparrini, A., Van Staa, T., Goldacre, B., Smeeth, L., & Bhaskaran, K. (2016) · BMJ · doi:10.1136/bmj.i3283 · Cited by 221
Pignone, M., Earnshaw, S., Tice, J. A., & Pletcher, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00007 · Cited by 204
“Men between 45 and 54 Years of Age Who Experienced Coronary Heart Disease Events within 10 Years* Event Patients Receiving No Treatment, n Patients Receiving Treatment with Aspirin Alone, n Patients Receiving Treatment with Aspirin plus a Statin, n Myocardial infarction 34 177 25 110 17 819 Stroke (ischemic and hemorr…”
BackgroundMethodInfluentialSelf-citationBooth, H. P., Prevost, T. A., Wright, A. J., & Gulliford, M. C. (2014) · Family Practice · doi:10.1093/fampra/cmu064 · Cited by 144
Petrilla, A. A., Benner, J. S., Battleman, D. S., Tierce, J. C., & Hazard, E. H. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00704.x · Cited by 89
Impact of Smoking Status on Long-Term Mortality in Patients With Acute Myocardial Infarction
Kinjo, K., Sato, H., Sakata, Y., Nakatani, D., Mizuno, H., Shimizu, M., Sasaki, T., Kijima, Y., Nishino, M., Uematsu, M., et al. (2005) · Circulation Journal · doi:10.1253/circj.69.7 · Cited by 59
Recruitment methods for united states Alzheimer disease prevention trials
Schneider, L. S. (2012) · The Journal of nutrition, health and aging · doi:10.1007/s12603-012-0011-6 · Cited by 22
Unal, B., Critchley, J., & Capewell, S. (2003) · Tobacco Induced Diseases · doi:10.1186/1617-9625-1-3-185 · Cited by 8
Metadata
- Authors
- Pignone, M.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2000-10-21
- Volume
- 321
- Issue
- 7267
- Pages
- 983-986
- ISSN
- 0959-8138 (ISSN-L)
- OpenAlex
- W1983625180
- Cited by
- 259
- References
- 31
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.